Background: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for treatment. Objectives: To enable data to be collected worldwide on FFA using common criteria and assessment methods. Methods: A multicentre, international group of experts in hair loss was convened by email to create consensus recommendations for clinical trials. Consensus was defined at > 90% agreement on each recommended part of these guidelines. Results: Standardized diagnostic criteria, severity rating, staging, and investigator and patient assessment of scalp hair loss and other clinical features of FFA were created. Conclusions: These guidelines should allow the collection of reliable aggregate data on FFA and advance efforts in both clinical and basic research to close knowledge gaps in this condition.
|Original language||English (US)|
|Number of pages||11|
|Journal||British Journal of Dermatology|
|Early online date||Jun 9 2021|
|State||Published - Aug 13 2021|
Bibliographical noteFunding Information:
sources Duke University Hair Research Fund and the Foundation for the Advancement of Hair Disorders.
© 2021 British Association of Dermatologists